journal
preproof
j
u
r
n
l
p
r
e
p
r
f
abstract
aim
new
human
coronaviru
hcov
design
began
spread
decemb
wuhan
citi
china
caus
pneumonia
call
spread
faster
coronavirus
succeed
cross
animalhuman
barrier
concern
new
viru
spread
around
world
previou
two
hcovssever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
caus
approxim
death
year
respect
thu
far
death
report
confirm
infect
countri
main
method
studi
rnadepend
rna
polymeras
rdrp
newli
emerg
coronaviru
model
valid
target
use
differ
antipolymeras
drug
current
market
approv
use
variou
virus
key
find
result
suggest
effect
ribavirin
remdesivir
sofosbuvir
galidesivir
tenofovir
potent
drug
sinc
tightli
bind
rdrp
addit
result
suggest
guanosin
deriv
setrobuvir
yak
top
seed
antivir
treatment
high
potenti
fight
strain
specif
signific
avail
fdaapprov
antirdrp
drug
help
treat
patient
reduc
danger
mysteri
new
viral
infect
drug
mention
tightli
bind
rdrp
strain
thu
may
use
treat
diseas
toxic
measur
requir
drug
sinc
previous
test
prior
approv
fda
keyword
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
rdrp
molecular
dock
structur
bioinformat
drug
repurpos
outbreak
yang
ten
day
later
declar
public
health
emerg
intern
concern
pheic
declar
pandem
day
later
symptom
includ
fever
malais
dri
cough
short
breath
respiratori
distress
hui
et
al
journal
preproof
drug
either
current
market
clinic
trial
stop
infect
immedi
ribavirin
remdesivir
sofosbuvir
galidesivir
tenofovir
show
promis
result
use
newli
emerg
strain
coronaviru
besid
setrobuvir
yak
compound
exhibit
excel
result
bind
rdrp
suggest
util
gtp
seed
obtain
specif
inhibitor
rdrp
use
highqual
model
j
u
r
n
l
p
r
e
p
r
f
acknowledg
mr
kauther
shaltoot
appreci
kind
help
support
without
work
possibl
prof
dr
wael
elshemey
appreci
guidanc
perform
dock
calcul
comput
facil
decemb
rapid
widespread
outbreak
novel
coronaviru
design
emerg
citi
wuhan
china
bogoch
et
al
hui
et
al
rothan
byrareddi
accord
world
health
organ
surveil
draft
januari
travel
wuhan
citi
hubei
provinc
week
onset
symptom
suspect
infect
bogoch
et
al
organ
addit
distribut
interim
guidanc
laboratori
carri
test
newlyemerg
outbreak
well
infect
prevent
control
guidanc
organ
b
pneumonia
suspect
origin
seafood
market
unknown
anim
respons
emerg
novel
viru
hui
et
al
surveil
border
around
globe
attempt
prevent
spread
new
mysteri
coronaviru
parr
two
month
ago
midjanuari
case
confirm
posit
leav
one
person
dead
critic
care
yang
number
continu
increas
day
number
confirm
case
time
write
exceed
confirm
death
mostli
china
europ
islam
republ
iran
januari
nation
health
commiss
china
confirm
humantohuman
transmiss
covidj
u
r
n
l
p
r
e
p
r
f
base
nucleotid
sequenc
member
betacoronavirus
sar
mer
hcov
chan
et
al
ibrahim
et
al
current
seven
differ
strain
human
coronavirus
hcov
report
includ
strain
hcov
alphacoronavirus
sar
mer
hcov
betacoronavirus
hui
et
al
sar
mer
hcov
wellknown
aggress
strain
coronavirus
caus
approxim
death
accord
mortal
rate
sar
mer
hcov
respect
et
al
hemida
alnaeem
organ
next
month
reveal
mortal
new
viru
nearli
mortal
rate
flank
viral
spread
may
mean
million
death
hcov
positivesens
long
bp
singlestrand
rna
virus
two
group
protein
character
hcov
structur
protein
spike
mark
coronavirus
nucleocapsid
n
matrix
envelop
e
nonstructur
protein
proteas
rdrp
rdrp
crucial
viral
enzym
life
cycl
rna
virus
henc
target
variou
viral
infect
includ
hepat
c
viru
hcv
zika
viru
zikv
coronavirus
cov
elfiki
elfiki
elfiki
elshemey
elfiki
et
al
elfiki
ismail
elfiki
ismail
ganesan
barakat
activ
rdrp
site
highli
conserv
two
success
surfaceaccess
aspart
betaturn
structur
doubli
ellenberg
elfiki
elfiki
ismail
studi
rdrp
model
built
use
sar
rdrp
solv
structur
ncbi
protein
data
bank
berman
et
al
model
valid
j
u
r
n
l
p
r
e
p
r
f
molecular
dock
perform
test
sever
directact
antivir
daa
drug
rdrp
includ
fdaapprov
medic
use
treat
hcv
human
immunodefici
viru
hiv
ebola
viru
compound
clinic
trial
hcv
two
neg
control
compound
addit
physiolog
nucleotid
gtp
ctp
utp
atp
result
promis
suggest
possibl
inhibit
current
avail
therapeut
newli
emerg
coronaviru
wu
et
al
newlyemerg
nucleotid
gene
retriev
nation
center
biotechnolog
inform
ncbi
nucleotid
databas
ncbi
homolog
model
rdrp
built
use
swiss
model
web
server
biasini
et
al
use
sar
hcov
solv
structur
pdb
id
chain
templat
build
model
sinc
sequelog
solv
structur
sequenc
ident
rdrp
sar
hcov
nonstructur
protein
solv
structur
cryoelectron
microscopi
resolut
deposit
protein
data
bank
kirchdoerf
ward
two
web
server
use
examin
model
molprob
web
server
duke
univers
structur
analysi
verif
server
save
univers
california
lo
angel
ucla
save
william
et
al
variou
type
softwar
use
judg
valid
model
procheck
laskowski
et
al
verifi
eisenberg
et
al
prove
joan
pontiu
errat
hooft
et
al
addit
ramachandran
plot
molprob
web
server
valid
model
optim
classic
j
u
r
n
l
p
r
e
p
r
f
mechan
use
forc
field
assist
comput
chemistri
workspac
scigress
fujitsu
elfiki
elfiki
elshemey
elfiki
ismail
summer
et
al
model
minim
perform
addit
miss
hydrogen
atom
prepar
dock
studi
lii
alling
autodock
vina
softwar
util
dock
experi
optim
rdrp
model
dock
target
trott
olson
addit
sar
hcov
rdrp
pdb
id
hepat
c
viru
hcv
nonstructur
protein
rdrp
pdb
id
use
dock
target
comparison
total
compound
test
sar
hcov
hcv
rdrp
name
four
physiolog
nucleotid
gtp
utp
ctp
atp
five
approv
drug
differ
viral
rdrp
galidesivir
remdesivir
tenofovir
sofosbuvir
ribavirin
compound
current
clinic
trial
hcv
rdrp
uprifosbuvir
setrobuvir
balaprevir
cmethylcytidin
yak
valopectibin
two
neg
control
compound
affin
toward
rdrp
cinnamaldehyd
thymoquinon
compound
prepar
optim
activ
form
physiolog
condit
elfiki
ismail
dock
structur
examin
use
proteinligand
interact
profil
plip
web
server
technic
univers
dresden
salentin
et
al
base
sequenc
ident
sar
rdrp
swiss
model
construct
valid
highqual
model
figur
b
sar
hcov
secondari
structur
pdb
id
shown
top
msa
water
access
found
bottom
highli
access
residu
blue
buri
residu
white
activ
site
residu
circl
mark
msa
impli
msa
activ
site
highli
conserv
water
access
strain
human
coronavirus
red
highlight
indic
ident
residu
yellow
highlight
repres
conserv
residu
region
surround
residu
also
conserv
mostli
surfac
access
hcov
rdrp
percent
sequenc
ident
valu
sar
mer
hcov
strain
found
respect
therefor
sar
hcov
rdrp
determin
sequelog
strain
rdrp
could
build
reliabl
model
complet
nucleotid
genom
determin
sequenc
ident
bat
sarslik
coronaviru
isol
sar
coronaviru
zsc
respect
rdrp
model
residu
gener
homolog
model
use
swiss
model
web
server
sar
hcov
rdrp
pdb
id
chain
employ
templat
model
exhibit
high
sequenc
ident
templat
suggest
excel
model
obtain
test
model
valid
mediat
ramachandran
plot
residu
allow
region
favor
region
residu
averag
score
errat
overal
qualiti
factor
prior
test
ligand
rdrp
structur
small
molecul
ensur
optim
activ
triphosph
form
optim
perform
use
classic
forc
field
follow
semiempir
forc
field
transit
state
check
optim
perform
use
function
densiti
function
theori
dft
quantum
mechan
beck
leach
lii
alling
stewart
dock
experi
activ
site
aspart
sar
rdrp
hcv
rdrp
treat
flexibl
ligand
also
flexibl
grid
box
center
rdrp
sar
rdrp
hcv
rdrp
respect
use
dock
experi
util
autodock
j
u
r
n
l
p
r
e
p
r
f
tool
morri
et
al
figur
show
dock
score
valu
blue
column
sar
hcov
orang
column
hcv
rdrp
gray
column
physiolog
compound
gtp
utp
ctp
atp
exhibit
bind
energi
atp
gtp
kcalmol
two
neg
control
compound
cinnamaldehyd
thymoquinon
display
low
bind
energi
rdrp
kcalmol
five
approv
drug
galidesivir
remdesivir
tenofovir
sofosbuvir
ribavirin
surround
dashedgreen
box
figur
also
abl
bind
rdrp
bind
energi
kcalmol
respect
drug
abl
bind
new
coronaviru
strain
rdrp
tightli
henc
may
contradict
polymeras
function
addit
drug
potenti
candid
inhibit
rdrp
hcv
kcalmol
sar
kcalmol
compound
current
clinic
trial
bind
rdrp
show
promis
result
setrobuvir
yak
surround
reddash
rectangl
figur
exhibit
firm
bind
rdrp
kcalmol
respect
rdrp
bind
energi
valu
rdrp
compound
better
nativ
nucleotid
guanosin
deriv
compet
gtp
bind
slightli
better
bind
kcalmol
gtp
kcalmol
analysi
dock
complex
requir
unravel
bind
mode
rdrp
investig
possibl
reason
differ
bind
energi
examin
form
complex
help
plip
web
server
figur
show
form
interact
ligand
gtp
ribavirin
sofosbuvir
tenofovir
rdrp
dock
gtp
found
form
hbond
rdrp
residu
j
u
r
n
l
p
r
e
p
r
f
addit
gtp
built
six
salt
bridg
two
interact
rdrp
vast
number
interact
give
complex
stabil
kcalmol
bind
energi
compar
gtpderiv
shown
figur
base
bind
energi
best
compound
discov
setrobuvir
kcalmol
kcalmol
yak
kcalmol
previous
mention
exhibit
interact
pattern
parent
nucleotid
gtp
bind
rdrp
hand
setrobuvir
yak
form
hbond
hydrophob
contact
contact
halogen
interact
setrobuvir
form
hbond
three
hydrophob
contact
interact
halogen
interact
yak
hbond
two
hydrophob
j
u
r
n
l
p
r
e
p
r
f
contact
interact
halogen
interact
residu
setrobuvir
seen
figur
b
summari
five
approv
drug
galidesivir
remdesivir
tenofovir
sofosbuvir
ribavirin
bind
rdrp
bind
energi
compar
nativ
nucleotid
see
graphic
abstract
moreov
compound
setrobuvir
yak
tightli
bind
newlyemerg
coronaviru
rdrp
henc
contradict
function
protein
lead
viral
erad
addit
use
seed
new
compound
specif
rdrp
activ
site
optim
compound
use
highqual
model
rdrp
may
result
perfect
compound
abl
stop
newlyemerg
infect
januari
declar
pandem
public
health
emerg
intern
concern
pheic
newli
emerg
coronaviru
wuhan
citi
hubei
provinc
china
health
concern
given
last
outbreak
type
viru
